Company intelligence / Profile preview

Targepeutics, Inc.

Hershey, Pennsylvania, United Statestargepeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Targepeutics is developing GB-13, a targeted immunotoxin that specifically targets the cancer-associated IL13Rα2 receptor. GB-13 has shown superior specificity and efficacy in pre-clinical studies compared to wild-type IL-13-based cytotoxin. The company has obtained orphan drug designation for GB-13 from the FDA and is working to advance it to clinical trials.

Therapeutic areas: Oncology
Modalities: Targeted immunotoxinMolecularly targeted therapeutics
Industry: Biotech

Drug pipeline

1 asset

Glioblast-13

Unknown

Partnerships

NABTT (New Approaches to Brain Tumor Therapy)

Beyond the preview

Go deeper on Targepeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Targepeutics, Inc..

Explore the full profile